 |
|
MAFLD: How is it different from NAFLD?
Cameron Gofton, Yadhavan Upendran, Ming-Hua Zheng, Jacob George
Clin Mol Hepatol. 2023;29(Suppl):S17-S31. Published online 2022 Nov 29 DOI: https://doi.org/10.3350/cmh.2022.0367
|
|
Citations to this article as recorded by
 Pre-MASLD: Should it be defined separately?
Hang-Kai Huang, You-Ming Li, Cheng-Fu Xu
Hepatobiliary & Pancreatic Diseases International.2024; 23(1): 1. CrossRef Object detection: A novel AI technology for the diagnosis of hepatocyte ballooning
Tian‐Lei Zheng, Jun‐Cheng Sha, Qian Deng, Shi Geng, Shu‐Yuan Xiao, Wen‐Jun Yang, Christopher D. Byrne, Giovanni Targher, Yang‐Yang Li, Xiang‐Xue Wang, Di Wu, Ming‐Hua Zheng
Liver International.2024; 44(2): 330. CrossRef Steatotic liver disease, MASLD and risk of chronic kidney disease
Josh Bilson, Alessandro Mantovani, Christopher D. Byrne, Giovanni Targher
Diabetes & Metabolism.2024; 50(1): 101506. CrossRef Role of autophagy in betaine-promoted hepatoprotection against non-alcoholic fatty liver disease in mice
Jinuk Seo, Doyoung Kwon, Sou Hyun Kim, Mi Ran Byun, Yun-Hee Lee, Young-Suk Jung
Current Research in Food Science.2024; 8: 100663. CrossRef Taohe Chengqi decoction alleviated metabolic-associated fatty liver disease by boosting branched chain amino acids catabolism in the skeletal muscles of type 2 diabetes mellitus
Ziqiao Yuan, Hui Qiao, Ziwei Wang, Haoran Wang, Mingru Han, Wenzhou Zhang, Yang Zhou, Hozeifa Mohamed Hassan, Wen Zhao, Tingting Qin
Phytomedicine.2024; 126: 155315. CrossRef Non-Pharmacological Approach to Diet and Exercise in Metabolic-Associated Fatty Liver Disease: Bridging the Gap between Research and Clinical Practice
Hassam Ali, Muhammad Shahzil, Vishali Moond, Maria Shahzad, Abhay Thandavaram, Alina Sehar, Haniya Waseem, Taha Siddiqui, Dushyant Singh Dahiya, Pratik Patel, Hans Tillmann
Journal of Personalized Medicine.2024; 14(1): 61. CrossRef Mortality in metabolic dysfunction-associated steatotic liver disease: A nationwide population-based cohort study
Eugene Han, Byung-Wan Lee, Eun Seok Kang, Bong-Soo Cha, Sang Hoon Ahn, Yong-ho Lee, Seung Up Kim
Metabolism.2024; 152: 155789. CrossRef Performance Evaluation of a Novel Non-Invasive Test for the Detection of Advanced Liver Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease
Anna Stefanska, Katarzyna Bergmann, Szymon Suwała, Aneta Mankowska-Cyl, Marek Kozinski, Roman Junik, Magdalena Krintus, Mauro Panteghini
Metabolites.2024; 14(1): 52. CrossRef Performance of noninvasive seromarkers in predicting liver fibrosis among MAFLD patients with or without viral hepatitis
Chung‐Feng Huang, Po‐Cheng Liang, Chih‐Wen Wang, Tyng‐Yuan Jang, Po‐Yao Hsu, Pei‐Chien Tsai, Yu‐Ju Wei, Ming‐Lun Yeh, Ming‐Yen Hsieh, Yi‐Hung Lin, Chao‐Kuan Huang, Chia‐Yen Dai, Jee‐Fu Huang, Wan‐Long Chuang, Ming‐Lung Yu
The Kaohsiung Journal of Medical Sciences.2024; 40(4): 374. CrossRef Time-restricted eating and supervised exercise for improving hepatic steatosis and cardiometabolic health in adults with obesity: protocol for the TEMPUS randomised controlled trial
Alba Camacho-Cardenosa, Antonio Clavero-Jimeno, Juan J Martin-Olmedo, Francisco Amaro-Gahete, Rocío Cupeiro, María Trinidad González Cejudo, Patricia Virginia García Pérez, Carlos Hernández-Martínez, Raquel Sevilla-Lorente, Alejandro De-la-O, Alejandro Ló
BMJ Open.2024; 14(1): e078472. CrossRef Association of sex-specific body mass index and waist circumference trajectories with non-alcoholic fatty liver disease incidence based on growth mixture modeling
Tengrui Cao, Chao Tong, Qiang Li, Yumei Han, Aheyeerke Halengbieke, Xuetong Ni, Bo Gao, Deqiang Zheng, Xinghua Yang
Nutrition, Metabolism and Cardiovascular Diseases.2024; 34(5): 1245. CrossRef Increased risk of colorectal adenomas with metabolic-associated fatty liver disease components
Dongsheng Ran, ChunLing Xin, Yingcai Ma, Yanyan Lu
Clinics and Research in Hepatology and Gastroenterology.2024; 48(3): 102302. CrossRef A Cross-Sectional Investigation for Prevalence and Risk Factors of Non-Alcoholic Fatty Liver Disease in Tibetan College Students in Mainland
娟 周
Advances in Clinical Medicine.2024; 14(02): 2843. CrossRef The Global Epidemic of Metabolic Fatty Liver Disease
Ethan C. Z. Lee, Vickram V. Anand, Alex C. Razavi, Pamela L. Alebna, Mark D. Muthiah, Mohammad S. Siddiqui, Nicholas W. S. Chew, Anurag Mehta
Current Cardiology Reports.2024; 26(4): 199. CrossRef Liver sinusoidal endothelial cells as potential drivers of liver fibrosis (Review)
Jiaqin Gao, Bin Zuo, Yang He
Molecular Medicine Reports.2024;[Epub] CrossRef Evolving role of semaglutide in NAFLD: in combination, weekly and oral administration
Evgenia Koureta, Evangelos Cholongitas
Frontiers in Pharmacology.2024;[Epub] CrossRef Association between remnant cholesterol and insulin resistance levels in patients with metabolic-associated fatty liver disease
Shuang Wang, Qiang Zhang, Bo Qin
Scientific Reports.2024;[Epub] CrossRef Identification of crosstalk genes relating to ECM‐receptor interaction genes in MASH and DN using bioinformatics and machine learning
Chao Chen, Yuxi He, Ying Ni, Zhanming Tang, Wensheng Zhang
Journal of Cellular and Molecular Medicine.2024;[Epub] CrossRef Serum PRO‐C3 is useful for risk prediction and fibrosis assessment in MAFLD with chronic kidney disease in an Asian cohort
Liang‐Jie Tang, Dan‐Qin Sun, Sherlot Juan Song, Terry Cheuk‐Fung Yip, Grace Lai‐Hung Wong, Pei‐Wu Zhu, Sui‐Dan Chen, Morten Karsdal, Diana Julie Leeming, Pei Jiang, Cong Wang, Qiang Chen, Christopher D. Byrne, Giovanni Targher, Mohammed Eslam, Jacob Georg
Liver International.2024; 44(5): 1129. CrossRef Non-invasive diagnosis of non-alcoholic fatty liver disease: Current status and future perspective
Jia-Lan Wang, Su-Wen Jiang, Ai-Rong Hu, Ai-Wu Zhou, Ting Hu, Hong-Shan Li, Ying Fan, Ken Lin
Heliyon.2024; 10(5): e27325. CrossRef Association of multiple serum minerals and vitamins with metabolic dysfunction-associated fatty liver disease in US adults: National Health and Nutrition Examination Survey 2017–2018
Peisen Guo, Jiahui Yu
Frontiers in Nutrition.2024;[Epub] CrossRef Metabolic dysfunction-associated fatty liver disease: current therapeutic strategies
Khamis Al Hashmi, Rosaria Vincenza Giglio, Anca Pantea Stoian, Angelo Maria Patti, Khalid Al Waili, Khalid Al Rasadi, Marcello Ciaccio, Manfredi Rizzo
Frontiers in Nutrition.2024;[Epub] CrossRef Depression and hepatobiliary diseases: a bidirectional Mendelian randomization study
Yu Kong, Zhongcai Yao, Lingli Ren, Liqin Zhou, Jinkai Zhao, Yuanyuan Qian, Dayong Lou
Frontiers in Psychiatry.2024;[Epub] CrossRef A universal plasma metabolites-derived signature predicts cardiovascular disease risk in MAFLD
Zhonglin Li, Rui Gong, Huikuan Chu, Junchao Zeng, Can Chen, Sanping Xu, Lilin Hu, Wenkang Gao, Li Zhang, Hang Yuan, Zilu Cheng, Cheng Wang, Meng Du, Qingjing Zhu, Li Zhang, Lin Rong, Xiaoqing Hu, Ling Yang
Atherosclerosis.2024; 392: 117526. CrossRef Hydroxytyrosol Linoleoyl Ether Ameliorates Metabolic-Associated Fatty Liver Disease Symptoms in Obese Zucker Rats
Rubén Tovar, Marialuisa de Ceglia, Miguel Rodríguez-Pozo, Antonio Vargas, Ana Gavito, Juan Suárez, Anna Boronat, Rafael de la Torre, Fernando Rodríguez de Fonseca, Elena Baixeras, Juan Decara
ACS Pharmacology & Translational Science.2024;[Epub] CrossRef Type 1 diabetes mellitus and non-alcoholic fatty liver disease: a two-sample Mendelian randomization study
Lin Tuo, Li-ting Yan, Yi Liu, Xing-xiang Yang
Frontiers in Endocrinology.2024;[Epub] CrossRef Examining the Pathogenesis of MAFLD and the Medicinal Properties of Natural Products from a Metabolic Perspective
Yansong Fu, Zhipeng Wang, Hong Qin
Metabolites.2024; 14(4): 218. CrossRef Evidence related to a vegetarian diet and metabolic dysfunction-associated steatotic liver disease: protocol for a scoping review
Kasey Moss, Victor Gitman, M Ines Pinto Sanchez, Simon Oczkowski, David Armstrong, Saumya Jayakumar, Constantine Jason Karvellas, Nazia Selzner, Joanna Dionne
BMJ Open.2024; 14(4): e079750. CrossRef Risk of Hepatocellular Carcinoma by Steatotic Liver Disease and Its Newly Proposed Subclassification
Byeong Geun Song, Aryoung Kim, Myung Ji Goh, Wonseok Kang, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Dong Hyun Sinn
Liver Cancer.2024; : 1. CrossRef Prevalence of Nonalcoholic Fatty Liver Disease [NAFLD] and Metabolic dysfunction associated Fatty Liver Disease [MAFLD] in patients with Irritable Bowel Syndrome [IBS]
Md. Musab Khalil, Sirajam Munira, Md. Mahbubul Alam, Al Mahmood Appolo, Musatafa Md. Abu Sayeed, Atikul Islam, Narwana Khaleque, Mohammad Faisal, Arifa Tasnim, Ruma Najnin, Mahmudur Rahman, Enamul Karim, Md. Golam Kibria
SN Comprehensive Clinical Medicine.2024;[Epub] CrossRef Obesity in Adults: Position Statement of Polish Association for the Study on Obesity, Polish Association of Endocrinology, Polish Association of Cardiodiabetology, Polish Psychiatric Association, Section of Metabolic and Bariatric Surgery of the Associati
Magdalena Olszanecka-Glinianowicz, Artur Mazur, Jerzy Chudek, Beata Kos-Kudła, Leszek Markuszewski, Dominika Dudek, Piotr Major, Piotr Małczak, Wiesław Tarnowski, Paweł Jaworski, Elżbieta Tomiak
Nutrients.2023; 15(7): 1641. CrossRef Changing the nomenclature from nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease is more than a change in terminology
Eileen Laurel Yoon, Dae Won Jun
Clinical and Molecular Hepatology.2023; 29(2): 371. CrossRef Type 2 Diabetes Mellitus, Non-Alcoholic Fatty Liver Disease, and Metabolic Repercussions: The Vicious Cycle and Its Interplay with Inflammation
Rafał Frankowski, Mateusz Kobierecki, Andrzej Wittczak, Monika Różycka-Kosmalska, Tadeusz Pietras, Kasper Sipowicz, Marcin Kosmalski
International Journal of Molecular Sciences.2023; 24(11): 9677. CrossRef MAFLD might be better in identifying subjects with sarcopenia or cardiovascular risk than NAFLD: A nationwide study
Eugene Han, Ho Soo Chun, Yong‐ho Lee, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Byung‐Wan Lee, Eun Seok Kang, Bong‐Soo Cha, Sang Hoon Ahn, Seung Up Kim
Journal of Gastroenterology and Hepatology.2023; 38(9): 1598. CrossRef The impact of concomitant metabolic dysfunction-associated fatty liver disease on adverse outcomes in patients with hepatitis B cirrhosis: a propensity score matching study
Xinyu Wang, Shuhang Wei, Yingnan Wei, Xueqi Wang, Feng Xiao, Yuemin Feng, Qiang Zhu
European Journal of Gastroenterology & Hepatology.2023; 35(8): 889. CrossRef Metabolic dysfunction: The silenced connection with fatty liver disease
Mariana M. Ramírez-Mejía, Xingshun Qi, Ludovico Abenavoli, Manuel Romero-Gómez, Mohammed Eslam, Nahum Méndez-Sánchez
Annals of Hepatology.2023; 28(6): 101138. CrossRef MAFLD: an optimal framework for understanding liver cancer phenotypes
Harry Crane, Cameron Gofton, Ankur Sharma, Jacob George
Journal of Gastroenterology.2023; 58(10): 947. CrossRef Liver Fibrosis Scores and Coronary Artery Disease: Novel Findings in Patients with Metabolic Dysfunction-Associated Fatty Liver Disease
Chuan Lu, Yan Chen, Yue Zhang, Xin Zhao
Diabetes, Metabolic Syndrome and Obesity.2023; Volume 16: 2627. CrossRef Current insights into the interplay between gut microbiota-derived metabolites and metabolic-associated fatty liver disease
Rachmad Anres Dongoran, Fang-Cen Tu, Chin-Hung Liu
Tzu Chi Medical Journal.2023; 35(4): 290. CrossRef New Insights into the Pathogenesis of Metabolic-Associated Fatty Liver Disease (MAFLD): Gut–Liver–Heart Crosstalk
Keungmo Yang, Myeongjun Song
Nutrients.2023; 15(18): 3970. CrossRef Meeting at the Crossroad between Obesity and Hepatic Carcinogenesis: Unique Pathophysiological Pathways Raise Expectations for Innovative Therapeutic Approaches
Konstantinos Arvanitakis, Stavros P. Papadakos, Vasileios Lekakis, Theocharis Koufakis, Ioannis G. Lempesis, Eleni Papantoniou, Georgios Kalopitas, Vasiliki E. Georgakopoulou, Ioanna E. Stergiou, Stamatios Theocharis, Georgios Germanidis
International Journal of Molecular Sciences.2023; 24(19): 14704. CrossRef Potential Therapeutic Strategies in the Treatment of Metabolic-Associated Fatty Liver Disease
Aleksandra Bołdys, Łukasz Bułdak, Mateusz Maligłówka, Stanisław Surma, Bogusław Okopień
Medicina.2023; 59(10): 1789. CrossRef Association between different modalities of insulin administration and metabolic dysfunction-associated fatty liver disease in adults with type 1 diabetes mellitus
Alessandro Csermely, Alessandro Mantovani, Mario Luca Morieri, Luisa Palmisano, Maria Masulli, Efisio Cossu, Marco Giorgio Baroni, Katia Bonomo, Flavia Agata Cimini, Gisella Cavallo, Raffaella Buzzetti, Carmen Mignogna, Frida Leonetti, Simonetta Bacci, Ro
Diabetes & Metabolism.2023; 49(6): 101477. CrossRef Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity
Gi-Ae Kim, Joon Ho Moon, Won Kim
Clinical and Molecular Hepatology.2023; 29(4): 831. CrossRef From nonalcoholic steatohepatitis, metabolic dysfunction-associated fatty liver disease, to steatotic liver disease: Updates of nomenclature and impact on clinical trials
Ming-Lun Yeh, Ming-Lung Yu
Clinical and Molecular Hepatology.2023; 29(4): 969. CrossRef The heterogeneity of metabolic syndrome presentation and challenges this causes in its pharmacological management: a narrative review focusing on principal risk modifiers
Amedeo Lonardo
Expert Review of Clinical Pharmacology.2023; 16(10): 891. CrossRef Vascular calcification: from the perspective of crosstalk
Shiqi Yang, Zhaolin Zeng, Qing Yuan, Qian Chen, Zuo Wang, Hui Xie, Jianghua Liu
Molecular Biomedicine.2023;[Epub] CrossRef What Is in a Name: from NAFLD to MAFLD and MASLD—Unraveling the Complexities and Implications
Mariana M. Ramírez-Mejía, Nahum Méndez-Sánchez
Current Hepatology Reports.2023; 22(4): 221. CrossRef Crosstalk between Lipids and Non-Alcoholic Fatty Liver Disease
Divyavani Gowda, Chandra Shekhar, Siddabasave Gowda B. Gowda, Yifan Chen, Shu-Ping Hui
Livers.2023; 3(4): 687. CrossRef Biological Role and Related Natural Products of SIRT1 in Nonalcoholic Fatty Liver
Decheng Meng, Fengxia Zhang, Wenfei Yu, Xin Zhang, Guoliang Yin, Pengpeng Liang, Yanan Feng, Suwen Chen, Hongshuai Liu
Diabetes, Metabolic Syndrome and Obesity.2023; Volume 16: 4043. CrossRef Recent Updates on the Therapeutic Prospects of Reversion-Inducing Cysteine-Rich Protein with Kazal Motifs (RECK) in Liver Injuries
Giuseppina Palladini, Laura Giuseppina Di Pasqua, Anna Cleta Croce, Andrea Ferrigno, Mariapia Vairetti
International Journal of Molecular Sciences.2023; 24(24): 17407. CrossRef Association between carotenoid intake and metabolic dysfunction-associated fatty liver disease among US adults: A cross-sectional study
Hang Zhang, Li Li, Lei Jia, Jinchun Liu
Medicine.2023; 102(51): e36658. CrossRef
|